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SOMMARIO 
La massa ventricolare sinistra (MVS) è un importante fenotipo clinico, la cui 
valutazione è in grado di predire eventi cardiovascolari avversi e morte prematura 
indipendentemente da sesso, provenienza etnica ed età. Un aumento della MVS si 
definisce, al di sopra di una determinata soglia, come ipertrofia ventricolare sinistra 
(IVS), ed è caratterizzata dall'ispessimento del ventricolo sinistro del cuore. In studi 
community-based, la presenza di IVS e l’aumento di MVS si sono dimostrate in 
grado di predire lo sviluppo di malattia coronarica, insufficienza cardiaca 
congestizia, ictus e malattie cardiovascolari. Questo fenotipo, quindi, non viene 
considerato solo come indicatore della struttura cardiaca, ma anche come fenotipo 
intermedio per stabilire l’esito clinico di varie malattie cardiovascolari. Diversi studi 
hanno indicato che la MVS è influenzata da fattori genetici. Allo scopo di 
identificare i geni che influenzano l’MVS, sono stati effettuati studi di linkage e di 
associazione genome-wide in diverse popolazioni, ma restano ancora da definire 
gran parte dell’ereditabilità e l'identità dei pathway e delle varianti funzionali; la 
promessa di predizione del rischio su base genetica non è quindi ancora 
realizzabile. 
Lo scopo dello studio è stato quello di indagare l'associazione tra varianti 
genetiche comuni e la massa ventricolare sinistra, mediante un approccio genome-
wide in una coorte di 966 soggetti non trattati con ipertensione lieve-moderata. 
Dall'analisi lineare, sono stati selezionati 85 polimorfismi a singolo nucleotide 
(SNP), con un p-value suggestivo di associazione (≤ 10
-5
). In particolare, alcuni 
SNP si trovano in geni con un ruolo nella patogenesi dell’ipertrofia cardiaca già 
riportato in letteratura, come ROCK1, IGF1, CACNA1D, FGFR1, TRAF5, SOX5, e 
KSR2. Ciascuno di essi potrebbero giocare un ruolo nel determinare il fenotipo, 
nonché far parte di pathway direttamente o indirettamente correlati alla 
fisiopatologia cardiaca. 
Per identificare gli alleli di rischio associati ai risultati più interessanti in relazione al 
fenotipo studiato, è stata effettuata un'analisi caso-controllo dividendo il nostro 
campione in due sottogruppi in base ai valori di MVS. La maggior parte degli SNP 
associati alla MVS nella regressione lineare presentano un’associazione 
significativa, dunque i portatori degli alleli di rischio hanno un odds ratio > 1 di 
avere una MVS aumentata, vale a dire di essere casi, rispetto ai controlli. Tuttavia, 
come per la maggior parte dei tratti complessi, gli odds ratio osservati sono 
modesti, quindi la loro rilevanza dal punto di vista clinico è ridotta. Abbiamo dunque 
definito uno score di rischio genetico aggregato e ponderato (wGRS), utilizzando 
l’effetto dell’allele di rischio (beta dell’analisi di regressione lineare) per spiegare la 
forza dell'associazione genetica di ogni allele. La possibilità di combinare più 
varianti in uno score di rischio genetico potrebbe essere interessante e aggiungere 
rilevanza ai risultati ottenuti.  
In conclusione, il nostro studio ci ha permesso di individuare dei geni il cui ruolo 
nella funzione cardiaca e/o ipertrofia cardiaca è stata dimostrata in precedenza da 
pubblicazioni di diversi autori. Inoltre, abbiamo evidenziato l'utilità di una misura 
aggregata di rischio di IVS nel discriminare i soggetti ad alto rischio. Tuttavia, i 
risultati devono essere interpretati nel contesto di alcune limitazioni e potenziali 
prospettive. Nessuno SNP ha raggiunto il livello di significatività di Bonferroni, 
probabilmente a causa della dimensione limitata del campione analizzato. Tuttavia, 
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l'omogeneità fenotipica della coorte analizzata e l'assenza di precedenti trattamenti 
antipertensivi, sono stati i presupposti dell’analisi per l'identificazione di veri effetti 
genetici. Una replica in una coorte indipendente è in genere necessaria per 
confermare ulteriormente i risultati; tuttavia una coorte indipendente con criteri 
simili non era disponibile per la replica. Inoltre, come spesso accade in studi di 
questo tipo, gli SNP significativi si trovano in regioni non codificanti, e questo fatto 
rende difficile spiegare il loro ruolo causale. Queste limitazioni tuttavia non 
sminuiscono la rilevanza dei geni identificati e confermati da lavori pubblicati in 
precedenza. 
Le prospettive future di questo studio dovrebbero essere la replica dei risultati in 
coorti indipendenti e la valutazione della capacità predittiva del wGRS di 
classificare correttamente i veri positivi e i veri negativi in base al loro background 
genetico. 
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ABSTRACT 
Left ventricular mass (LVM) is an important clinical phenotype, whose assessment 
can predict adverse cardiovascular events and premature death in all genders, 
races, and ages. Increase in LVM defines left ventricular hypertrophy (LVH) with 
the thickening of the left ventricle of the heart. In community-based cohorts, the 
presence of left ventricular hypertrophy (LVH) and increased LVM predict the 
development of coronary heart disease, congestive heart failure, stroke, and 
cardiovascular disease. Thus this trait serves not only as measures of cardiac 
structure, but also as intermediate phenotype for clinical cardiovascular disease 
outcome. Several studies have indicated that LVM is influenced by genetic factors. 
Genome wide linkage and association studies in diverse population have been 
performed to identify genes influencing LVM, but much of the heritability remains 
unexplained, the identity of the underlying gene pathways and functional variants 
remain unknown, and the promise of genetically based risk prediction remains 
unfulfilled.  
The aim of the study was to investigate the association of common genetic variants 
with left ventricular mass using a genome wide approach in a large cohort of never 
treated mild-to-moderate essential hypertensive subjects. From the linear analysis, 
we selected 85 single nucleotide polymorphisms (SNPs), with a suggestive p-value 
of association with LVM (≤ 10-5). In particular, some SNPs lying in genes 
previously described as having a role in the pathogenesis of cardiac hypertrophy, 
such as ROCK1, IGF1, CACNA1D, FGFR1, TRAF5, SOX5, and KSR2. Each of 
them might play a putative role in determining the LVM phenotype as well as other 
pathophysiological pathways directly or indirectly linked to cardiac pathophysiology.  
To assess the risk alleles associated to the most interesting findings in relation to 
the phenotype studied, we performed a case-control analysis by dividing our 
sample in two subsets according to LVM values. Most of the SNPs associated with 
LVM in linear regression presented a significant association, showing that the 
carriers of the risk alleles have an odds ratio higher than 1 to have increased LVM, 
i.e. to be cases respect to controls. Nevertheless as for most of the complex traits, 
the observed odds ratios are modest (except for those biased by the absence of 
homozygous risk genotypes), so their relevance for a clinical use is uncertain. 
Thus, we defined a weighted genetic risk score using the effect size of the risk 
allele (beta value of the linear regression analysis) to account for the strength of 
the genetic association with each allele. The possibility to combine more variants in 
a global genetic risk score could be interesting and could add relevance to the 
results. 
In conclusion, our GWAS allowed us to pinpoint genes whose role in heart function 
and/or cardiac hypertrophy has been demonstrated in previously publications by 
different authors. Moreover, we highlighted the usefulness of an aggregate 
measure of risk of LVH to discriminate high-risk subjects. However, the results 
must be interpreted within the context of some potential limitations and 
perspectives. No SNPs reached a Bonferroni’s significance level probably due to a 
limited sample size. However, the phenotypic homogeneity of our cohort and the 
absence of previous antihypertensive treatment are prerequisites for the 
identification of true genetic effects. A replication in independent cohorts is needed 
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to further confirm the findings; however an independent cohort with similar criteria 
was not available for replication. Moreover, it often happens, as in our study, the 
significant SNPs map in non-coding regions, making it difficult to explain their 
causative role. These limitations should not reduce the relevance of the genes 
identified and confirmed by previously published papers.  
Future perspectives of this study should be the replication of the GWAS findings in 
independent cohorts and the assessment in independent samples of the prediction 
ability of wGRS to correctly classify true positives and true negatives according to 
their genetic background. 
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1 INTRODUCTION 
1.1 DEFINING LVM 
Left ventricular mass (LVM) is an important clinical phenotype, whose 
assessment can predict adverse cardiovascular events and premature 
death in all genders, races, and ages [1]. Increase in LVM defines left 
ventricular hypertrophy (LVH) with the thickening of the left ventricle of the 
heart. The diagnosis of LVH has been incorporated in clinical practice as 
marker of cardiovascular risk [2]. Population-based studies have revealed 
that increased LVH provide prognostic information in hypertension, and in 
the general population, as well as in a variety of clinical settings [3 ]. 
Furthermore, regression of LVH appears to be a favorable prognostic 
marker independent of the treatment-induced blood pressure (BP) 
reduction [3].  
In the Sixties, the association of echocardiography LVH with cardiovascular 
events was first described in clinical and population-based studies. The 
20% of patients with LVM exceeding a predefined cut-off had approximately 
4-fold higher rate of morbid events (24%), than the patients without LVH 
(6%). Other studies have subsequently extended these findings by 
demonstrating that increased LVM strongly predicts cardiac and 
cerebrovascular morbidity and mortality, independent of traditional risk 
factors [ 4 ]. A report from the Framingham Heart Study showed that 
increased LVM strongly predicted all-cause of cardiac mortality and 
coronary heart disease events in adults over 40 years, independently of 
conventional risk factors. Incidence of stroke and transient ischemic attack 
was higher in the highest quartile than in the lowest one [5,6]. Similarly, in 
the Cardiovascular Health Study the incidence of congestive heart failure 
was higher in the highest quartile than in the lowest one [7]. Another 
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analysis from the Framingham Heart Study reports a linear relationship 
between LVM and the rate of future cardiovascular events [8].  
Therefore, LVM has been touted not only as measures of cardiac structure, 
but also as a suitable measure for cardiovascular disease (CVD) risk 
stratification and a marker for subclinical disease [9]. 
LVM shows a continuous distribution in the general population, whereas 
LVH defines the upper limit end of LVM distribution [3]. LVH is a common 
condition, both in the general population (in the United States occurs in 
16% of white and in 33-43% of black people) and in hypertensives (22-60% 
of US hypertensives) [10]. Although historically considered an adaptive 
response of the heart to hypertension, it is now recognized that the 
presence and magnitude of LVH varies substantially among individuals. At 
equal BP levels, some individuals develop LVH, whereas others do not. 
Because the major causes of morbidity and mortality among hypertensives 
are due to the cardiovascular (CV) manifestation of hypertension (i.e. LVH) 
and not to the level of blood pressure per se, it is important to understand 
the causes of LVH [10].  
1.2 DETERMINANTS OF LEFT VENTRICULAR MASS 
In both healthy individuals and patients with disease, LVM is likely to be 
determined by a combination of genetic factors and adaptive responses to 
environmental and mechanical factors.  
Gender and body size have been identified as predictors of LVM, and are 
used as covariates to corrected LVM measurement. LVH diagnosis is 
based on this corrected measure. Many other constitutional factors and 
exposures may lead to pathophysiological changes in LVM. 
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 Blood pressure and hypertension 1.2.1
Numerous population based studies have shown an association between 
hypertension and LVM [11,12,13]. The prevalence of LVH varies with 
severity of hypertension, ranging from < 20% in mild hypertension to almost 
100% in severe or complicated hypertension [14]. Even within the normal 
range, increases in blood pressure are related to an increased LVM, due to 
both hypertrophic response to increased overload, and to neuro-humoral 
and genetic factors.  
There is some evidence for involvement of the renin-angiotensin system 
(RAS), with impaired suppression of the RAS or increased sensitivity to 
angiotensin II appear to act as stimulus for LVH in hypertensive patients. 
Several studies confirm an association between increasing plasma renin 
activity levels and increased LVH [14]. Experimental evidences suggest 
that angiotensin II induces hypertrophy in myocytes and vascular smooth 
muscle cells and may regulate collagen synthesis. Aldosterone also may 
stimulate extracellular collagen deposition and myocardial fibrosis [14]. 
There is much evidence that dietary salt intake plays a role in the 
development of LVH in hypertensive patients, although the mechanism is 
not still clear [14].  
LVH is an independent risk factor for CVD in patients with hypertension. 
The underlying mechanisms for this association may include a combination 
of electrophysiological alterations, anatomical changes, and increased 
sympathetic RAS activity [14]. LVH is recognized as a hypertension-related 
target organ damage in several clinical practice guidelines, representing an 
intermediate unfavorable prognostic marker [2]. 
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 Age, gender and ethnicity 1.2.2
Several studies show a significant univariate association between age and 
LVM [5]. In the Framingham population, echocardiography-detected LVH 
prevalence ranged from 6% in persons under 30 years of age to 43% in 
those with ≥ 70 years [14]. LVM progressively increases during aging both 
in normotensive and hypertensive subjects [2]. However, multivariate 
analyses suggest that adjusting for lean mass, fat mass and blood pressure 
removes some or all of the relationship with age, suggesting that age 
differences in LVM are at least partly due to age differences in lean mass, 
fat mass and blood pressure [15,16,17]. Nevertheless it appears prudent to 
adjust for age, gender, and ethnicity in epidemiological investigations 
related to LVM and LVH [18]. 
Several studies report strong gender differences in LVM [19,20]. LVH 
detected by echocardiography was more prevalent in women than in men 
(2.9% vs. 1.5%), whereas echocardiographically detected LVH was more 
common in men than in women (17.6% vs. 14.2%) [21]. However, indexing 
LVM to lean mass or height2.7 usually results in similar LVM index values in 
men and women, suggesting that differences between men and women in 
lean body mass and body size account for most of the gender gap in LVM 
[22,23].  
Ethnicity also plays a role in the epidemiology of LVH. The prevalence of 
LVH is higher in African-Americans and Africans, and ancestry has been 
identified as an independent risk factor for LVH [2,24]. This is probably 
attributable, in part, to the elevated risk of hypertension in African-
Americans and Africans, with one study showing an almost fourfold 
increase in the incidence of LVH in blacks as compared to whites (odds 
ratio 3.7, 95% CI 3.2-4.4) [25,26]. Other studies show no race differences in 
either LVM indexed for body size or in the prevalence of LVH [27,28].  
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 Obesity and diabetes  1.2.3
Obesity has been shown independently associated to LVM [29], particularly 
in populations with high prevalence of hypertension and other metabolic 
risk factors [30,31]. Despite this association, the impact of obesity on LVM 
may be less than expected, thus “uncomplicated obesity” was not a risk 
factor for LVH indexed by body surface area (BSA) or height2.7 [32,33]. 
Together with obesity and hypertension, diabetes is an important 
determinant of LVM in most population-based studies [34,35,36,37]. 
 Other risk factors  1.2.4
Environmental exposure, such as alcohol consumption [38], salt intake [39], 
smoking [11,38], and physical activity in men [40] have been associated to 
increased LVM. Other factors such as blood lipids, pulmonary function, 
heart rate, low weight at one year-old, and hematocrit have also been 
implicated, but with some inconsistency among different studies 
[7,41,42,43]. Clinical validity and impact of those factors is controversial, 
but it may be important to consider them as potential confounders in 
epidemiological studies investigating the role of risk factors in LVH and the 
role of LVM in disease prediction [18]. 
1.3 LVM HERITABILITY 
Only one-half to two-thirds of the inter-individual variability of LVM can be 
explained by its clinical and hemodynamic correlates. Several studies have 
indicated that LVM is influenced by genetic factors [4]. Monozygotic twins 
have substantially more similar LVM than dizygotic twins [4]. Family-based 
studies have confirmed that echocardiographic measures of LVM, after 
adjustments for covariates, are heritable. Heritability of LVM estimated in 
studies of twins, hypertensive siblings, nuclear, and complex families 
ranged from 15 to 84% [44].  
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 1.3.1 Previous studies on genetics of LVM  
The normal distribution of LVM in populations suggests that this phenotype 
is a complex trait influenced by multiple genes. Genetic analysis indicates 
that the segregation of LVM was compatible with an additive polygenic 
model [45]. 
Candidate genes studies have shown a potential role of genetic 
polymorphisms located in angiotensin-converting enzyme (ACE) 
[46,47,48,49], aldosterone synthase (CYP11B2) [50], insulin-like growth 
factor (IGF1) [51], neuropeptide Y (NPY) [52], guanine nucleotide-binding 
protein 3 (GNB3) [ 53 ], endothelial nitric oxide synthase (eNOS) [ 54 ], 
peroxisome proliferator-activated receptor-alpha (PPARA) [ 55 ], and 
centlein centrosomal protein (CNTLN) [56] genes. Genome-wide linkage 
and association studies have shown an association between LVM and 
several loci located in different chromosomes. Particularly, in a whole 
genome linkage study of hypertensive families, three regions (10q23.1, 
12q14.1, 17p13.3) were found to approach suggestive evidence of linkage 
for particular measures of LVH [57]. A genome wide association study 
(GWAS) on Koreans reported a significative correlation between the 
skeletal muscle Ca(2+) channel protein RYR1 gene on chromosome 19 
and LVH [58]. The HyperGEN study identified a polymorphism in KCNB1 
gene associated with LVM using a genome wide approach [9]. A large 
meta-analysis identified loci associated with left ventricular structure on the 
solute carrier family 35, member F1 (SLC35F1) gene, the chromosome 6 
open reading frame 203 (C6orf203) and the phospholamban (PLN) gene 
[59]. Recently, Barve RA et al identified eleven SNPs with a suggestive 
association with left ventricular mass trait, in a comparative study between 
M-mode and 2D echocardiography and between raw LVM and BSA-
indexed LVM. One SNP lies in CDH13 gene were confirmed in all the four 
measures [60]. However, the physiopathological link between genes and 
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LVM remains unclear and these results explain only a small part of LVM 
variance. The main limits in association studies of LVM with gene variants 
in essential hypertension (EH) are a) the limited sample size of the study 
cohorts, and b) the presence of patients under antihypertensive treatment 
or after short wash-out periods. As long-term treatment with 
antihypertensive drugs modifies cardiac mass, large cohorts of never 
treated essential hypertensives are mandatory to study the association 
between LVM and gene variants, although we are perfectly aware of the 
difficulty to recruit large cohorts of such patients [61,62]. 
1.4 LEFT VENTRICULAR MEASUREMENT 
Given the clinical importance of LVM, it is essential to have a reliable 
method for its estimation. Echocardiography (ECG) has been clinically 
employed for more than 30 years, becoming one of the most important non-
invasive imaging methods in the evaluation of cardiac morphology and 
dynamics. Despite inherent limitations, conventional echocardiography 
continues to be the imaging modality of choice for the assessment of LVM 
in routine clinical practice. Echocardiography has been shown to reliably 
characterize LVM, and its use has been extensively validated in clinical 
care and in research [63,2]. 
A standard echocardiogram is also known as a transthoracic 
echocardiogram (TTE), or cardiac ultrasound. In this case, the 
echocardiography probe is placed on the thorax of the subject, and images 
are taken through the chest wall. This is a non-invasive, highly accurate 
and quick assessment of the overall health of the heart. An alternative way 
to perform an echocardiogram is transesophageal echocardiogram (TEE); 
TEE provides additional and more accurate information than TTE for some 
patients, for several specific diagnoses and for many catheter-based 
cardiac interventions [64].  
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 1.4.1 Imaging mode  
Motion-mode (M-mode), 2-dimensional echocardiography (2DE) and finally 
3-dimensional echocardiography (3DE) are the imaging modalities used to 
estimate LVM [65]. M-mode ECG was one of the earliest modalities of 
echocardiography to come into clinical use. It allows better endocardial 
border definition as it has greater resolution due to higher frame-rate; 2DE 
imaging, on the other hand, depicts the “real” ventricular shape, but has 
lower lateral resolution and frame-rate. 3DE is feasible in the clinical setting 
and provides fast and accurate assessment of LVM, which is superior to 
conventional echocardiographic methods, especially in distorted hearts 
[63].  
Although 2D or 3D echocardiography can be more accurate, M-mode was 
the first non-invasive imaging technique developed and remains the 
recommended method. Most epidemiological reports use M-mode imaging 
modality; preference for M-mode is based on its technical feasibility and 
availability at the time when most studies were performed [2].  
 1.4.2 Calculating and indexing left ventricular mass 
The most common used formulas to estimate LVM are all variations of the 
same mathematical principle, based on the volume formula; whether using 
M-mode, 2D, or 3D measurements, LVM estimation by echocardiography is 
based on subtraction of the left ventricular cavity volume from the volume 
enclosed by the correspondent epicardium to obtain left ventricle muscle or 
shell volume. This shell volume is then converted to mass by multiplying 
the myocardial density (taken to be 1.05 g/ml).  
To date, most LVM calculations have been made. The most used formula is 
that by Deveraux and colleagues, based on American Society of 
Echocardiography (ASE) criteria of edges definition: 
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𝐿𝑉𝑀 (𝐴𝑆𝐸) = 0.8 × {1.04 × [(𝐿𝑉𝐼𝐷 + 𝑃𝑊𝑇 + 𝐼𝑉𝑆𝑇)3 − (𝐿𝑉𝐼𝐷)3]}  + 0.6 𝑔 
This formula was validated on the necropsy findings of 52 individuals 
(r=0.9, p-value < 0.001) [66].  
In order to allow comparison of LVM among subjects of different body 
sizes, different allometric approaches have been suggested to normalize 
LVM: height, diverse allometric height adjustment, weight, body surface 
area, body mass index, and free-fat mass. However, the best way for LVM 
normalization is still controversial and results in different patient 
classifications. Body surface area was the first anthropometric variable 
used to index LVM and has shown a stronger statistical correlation than 
height with LVM, but underestimates the prevalence of obesity-related LVH 
[67]. Consequently, height has also been used for indexing (either height 
alone or height raised to an allometric power of 1.7 or 2.7). Indexation of 
LVM to height raised to an allometric exponent of 2.7 (LVM/height2.7) has 
shown better predictive value for CVD outcomes, better detection of 
obesity-related LVH, and less variability of LVM among normal individuals 
[68]. BSA has been widely adopted by the ASE and European Association 
of Cardiovascular Imaging as the preferred method for indexing LVM [65].  
 1.4.3 Determining cut-off points 
The determination of LVM cut points to define abnormality is a source of 
controversy and can be driven by different strategies. American Society of 
Echocardiography recommends reference values for LVM, obtained from 
an ethnically diverse population of 510 normal-weight, normotensive, and 
non-diabetic white, African American, and American Indian adults, without 
recognized cardiovascular disease [65]. Reference upper limits of normal 
LVM by linear measurements are reported in table 1. 
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Table 1 Reference limits and partition values for left ventricular mass, determined by linear M-mode imaging. 
 
Women 
 
Men 
 
Reference 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal  
Reference 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
LVM 
(g) 
67-162 163-186 187-210 ≥ 211 
 
88-224 225-258 259-292 ≥ 293 
LVM/BSA 
(g/m2) 
43-95 96-108 109-121 ≥ 122 
 
49-115 116-131 132-148 ≥ 149 
LVM/height 
(g/m) 
41-99 100-115 116-128 ≥ 129 
 
52-126 127-144 145-162 ≥ 163 
LVM/height2.7 
(g/m2.7) 
18-44 45-51 52-58 ≥ 59 
 
20-48 49-55 56-63 ≥ 64 
 
BSA, body surface area; LVM, left ventricular mass; 2D, 2-dimensional (adapted from Ref. 18).  
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2 AIM OF THE STUDY 
The aim of this exploratory study was to investigate the association of 
common genetic variants with left ventricular mass using a genome wide 
approach in a large cohort of never treated mild-to-moderate essential 
hypertensive subjects. After identification of some genetic susceptibility loci, 
we aimed to create a “weighted genetic risk score” that aggregates the 
measure of risk of increased LVM.  
By targeting intracellular signaling pathways involved in regulation of LVM, 
it should be possible to define therapeutic strategies for inhibiting 
hypertrophy of heart cells, and thus to reduce the risk of cardiac morbidity 
and mortality. 
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3 MATERIALS AND METHODS 
3.1 OVERVIEW 
Data presented in the study are part of the data generated within two 
projects: 1) “HYPERGENES Project” - European Network for Genetic 
Epidemiological Studies: building a method to dissect complex genetic trait, 
using essential hypertension as a disease model - which is a collaborative 
project financed by the European Commission in the 7th Framework 
Program [69]; 
2) “InterOmics Project” - Development of an integrated platform for the 
application of "omic" sciences to biomarker definition and theranostic, 
predictive and diagnostic profiles (financed by MIUR-CNR 
http://www.interomics.eu).  
3.2 STUDY PARTICIPANTS AND INCLUSION CRITERIA  
The analyzed sample consists of 1,029 newly diagnosed mild-to-moderate 
essential hypertensive patients - i.e. no previous antihypertensive treatment 
- of Caucasian origin. Patients were recruited using the following inclusion 
criteria: 1) baseline untreated BP levels in the hypertensive range (systolic 
BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg; 2) no previous 
antihypertensive treatment; 3) absence of comorbidities (i.e. type 1 and 
type 2 diabetes); 4) glycaemia  ≤ 150 mg/dL; 5) serum creatinine < 2 
mg/dL. 
They were enrolled during several pharmacogenomics studies, performed 
at the “Hypertension and Related Diseases Centre-AOU” - University of 
Sassari and at other eleven Clinical Research Centers all over Italy (table 
A1). The pharmacogenomics studies were developed also in collaboration 
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with the “Genomic and Bioinformatics Laboratory” of the University of Milan 
[69,70,71]. 
Participants who were all untreated underwent a run-in period of eight 
weeks under standardized dietary conditions to qualify the presence of EH. 
During this period, BP was measured weekly to meet the inclusion criteria 
whereas all the other measurements of cardiac, renal and metabolic 
phenotypes were performed after the run-in period. 
The study was approved by the Ethics Committee of the University of 
Sassari and supported by all the other local Ethics Committees. Written 
informed consent was obtained for the study and for the DNA analysis, and 
all clinical investigation was conducted according to the Declaration of 
Helsinki. 
3.3 PHENOTYPES 
3.3.1  LVM Quantitative phenotype 
Left ventricular dimensions were measured by transthoracic 
echocardiography according to the guidelines of ASE [18]. The linear 
internal measurements of the left ventricle (LV) were acquired in the 
parasternal long-axis view and obtained using M-mode tracing 
perpendicular to the LV long-axis immediately below the level of the mitral 
valve leaflet tips. The average of at least four consecutive measurements at 
the end-diastolic phase (R-wave peak of ECG trace) was considered to 
determine: interventricular septum thickness (IVST), left ventricular internal 
diameter (LVID), and posterior wall thickness (PWT). LVM was estimated 
using the Devereux equation [66], and indexed for height2.7 (LVMh2.7) [67]. 
Left ventricular hypertrophy was defined by left ventricular mass index > 48 
g/m2.7 in men and > 44 g/m2.7 in women [18]. TTE measurements were 
performed by different operators and blindly revised by a second operator: 
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the presence of different operators in the evaluation of LVM, although blind 
each other, was considered as a relevant covariate in the association 
analysis. 
3.3.2 Case-control phenotype 
We divided the sample according to LVM values: 158 subjects with 
abnormal LVM (≥ 52 g/m2.7 for women and ≥ 56 g/m2.7 for men) were 
identified as cases and 615 subjects with LVM in the normal range (≤ 44 
g/m2.7 for women and ≤ 48 g/m2.7 for men) were identified as controls. We 
did not consider subjects with intermediate LVM values (between 45 and 51 
g/m2.7 for women and between 49 and 55 g/m2.7 for men). We used as 
reference limits and partition values of LVM the values indicated by Lang 
RM and colleagues [18].  
3.4 GENETIC CHARACTERIZATION 
Genomic DNA was extracted from peripheral blood with standard 
procedures. Genotyping was performed with the Illumina Human1M-Duo 
array (Illumina Inc, San Diego, CA, USA) within HYPERGENES project 
(n=901) and the Illumina HumanOmniExpress array within the InterOmics 
project (n=139). Illumina Human1M-Duo array captures 1,199,187 genetic 
loci. In addition to markers necessary for broad genome coverage (of which 
672,002 within 10 Kb of RefSeq genes, 21,877 non-synonymous SNPs, 
and 483 Indel), the chip contains 51,207 markers in sex chromosomes, 138 
markers in mitochondrial DNA, 35,969 markers covering copy number 
variant regions, and 30,908 markers in MHC/ADME regions. Illumina 
HumanOmniExpress array captures > 713,014 markers. In addition to 
markers necessary for broad genome coverage (of which 395,094 within 10 
Kb of RefSeq genes, 12,286 non-synonymous and 10,854 synonymous), 
the chip contains 19,485 markers in sex chromosomes and 17,712 markers 
in HLA/ADME regions. Genotyping was performed at “Genomic and 
15 
 
Bioinformatics Laboratory” of University of Milan. Raw intensity data were 
analyzed with the Illumina software “GenomeStudio” for genotype calling 
(http://bioinformatics.illumina.com/informatics/sequencing-microarray-data-
analysis/genomestudio.html), using the Illumina reference cluster file. 
3.5  DATA QUALITY CONTROLS 
After the generation of raw genotyping data, we performed cleaning 
procedures that are crucial steps to avoid false positive and false negative 
results. All quality control (QC) steps were performed in accordance with 
the protocol by Anderson C.A. and colleagues [72], using PLINK software 
(version 1.07) [73]. SNPs and subjects that passed QCs have been then 
tested for imputation and further association analyses. 
3.5.1 Sex mismatches 
The gender information of each individual reported in clinical data records 
was compared to that estimated using X-chromosome markers. When sex 
discrepancies could not be resolved by clinicians who conducted 
phenotyping, the individuals were not considered in the analysis. 
3.5.2 Call rate per individual and per SNP 
The individual call rate is the proportion of genotypes per subject with non-
missing data. Accordingly, for each SNP, the call rate is the percentage of 
subjects with a non-missing genotype attribution. We filtered-out subjects 
with call rate < 0.98 and SNPs with call rate < 0.99. 
3.5.3 Minor Allele Frequency  
Minor allele frequency (MAF) is the lowest allele frequency at a specific 
locus observed in a particular population. MAF indicates how much 
frequently the minor allele of a SNP is found in the sample under study. We 
removed all SNPs with a very low MAF setting a threshold at 1%. 
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3.5.4 Heterozygosity 
We inspected the distribution of mean heterozygosity across all individuals, 
to identify subjects with excessive or reduced proportion of heterozygote 
genotypes, which may be indicative of DNA samples contamination or 
inbreeding respectively. Mean heterozygosity is calculated as (N(NM) − 
O(Hom))/N(NM), where [N(NM)] denotes the number of non-missing 
genotypes per individual and [O(Hom)] is the observed number of 
homozygous genotypes. We excluded all individuals with heterozygosity 
rate ± 3 standard deviations from the mean. 
3.5.5 Homogeneity analysis 
In order to identify duplicated or related individuals, we performed the 
homogeneity analysis of samples using a genome wide identity by descent 
(IBD) estimation. Two or more alleles are identical by descent if they are 
identical copies of the same ancestral allele. IBD estimation is based on the 
average proportion of alleles shared between subjects. We used estimates 
of pairwise IBD to find pairs of subjects who look too similar to each other, 
more than we would expect by chance in a random sample.  
3.5.6 Population stratification detection 
In order to identify subjects with large-scale differences in ancestry, we 
assessed the population stratification using the principal component 
analysis (PCA), as implemented in the EIGENSOFT package (version 3.0) 
[74,75]. For PCA we used SNPs in common between the two genotyping 
arrays (≈ 400 k). Population stratification is a major confounder in 
association studies that occurs when allele frequencies differ between 
subjects of the comparison samples due to ancestry differences, various 
ethnic backgrounds or even to “hidden” stratification. The presence of 
substructures in the population can lead to spurious association between a 
phenotype and unlinked candidate loci, causing either false positive of false 
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negative results. Based on principal components value for each individual, 
the software calculates a mean and a standard deviation. We removed 
genetic outliers, defined as individuals that exceed a default number of 
standard deviations (6.0) from the whole sample along any of the principal 
components. The first ten principal components (PCs) were selected to 
correct for stratification by including them as covariates in the linear 
regression model.  
3.6  IMPUTATION 
In order to infer genotypes at not directly typed loci, we performed a two-
step imputation method on markers of highest quality that consists of: 1) 
phasing of the typed genotype using SHAPEIT2 software [76 ] and 2) 
imputation of the genotypes on the reference panel, using Minimac [77]. We 
used the high-density panel of the 1000 Genomes Project as reference 
(www.1000genomes.org) [78] based on the release of March 2012, which 
integrates more than 39 million variants. 
Through imputation we could increase the overall number of markers 
available for association testing and we could also combine data from the 
two arrays used for genotyping. In fact, when a dataset is collected using 
two or more arrays with different sets of markers, some markers are not 
assayed across the entire dataset, because they were not present in both 
arrays. This limits the association analysis at those markers typed with both 
arrays. Using imputation, we could predict genotypes at loci that are not in 
common between the two genotyping arrays. Thus imputation increases 
the sample size at each marker in the total number of individuals genotyped 
across the entire study.  
Imputation accuracy was evaluated using “imputation R-square” (Rsq), a 
parameter provided by Minimac software, which estimates the squared 
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correlation between imputed and true genotypes, i.e. the ratio of the 
variance of imputed and true allele count [79].  
3.7 GENOTYPE-PHENOTYPE ASSOCIATION ANALYSES 
We performed two types of analyses: 1) a quantitative trait association 
analysis using the imputed allele dosages, as implemented in Mach2qtl 
[80]; 2) and a case-control analysis dividing our sample according to LVM 
values and focusing on SNPs significantly associated to LVM in the linear 
analysis. 
In the quantitative trait analysis, the analyzed phenotype was LVM 
estimated by Devereux equation, in accordance with the ASE criteria, and 
indexed for height2.7 (LVMh2.7), as described in the paragraph 3.3.1. To 
assess the genotype to phenotype association we performed a linear 
regression on LVMh2.7, under an additive model, adjusting for some 
covariates: sex, systolic and diastolic blood pressure (SBP, DBP), serum 
creatinine, urinary sodium 24 h (uNa24h), sitting plasma renin activity 
(sPRA), body mass index (BMI), heart rate (HR), first ten PCs, and TTE 
operator. The selection of covariates to be included in the model was 
performed through analysis of variance (ANOVA), as implemented in 
StataSE. To estimate significance threshold, results was controlled for 
multiple testing using Bonferroni’s adjustment.  
For case-control analysis, we divided the sample according to LVM values 
as described in the paragraph 3.3.2. We performed a logistic regression 
adjusting for the above-mentioned covariates.  
3.8 WEIGHTED GENETIC RISK SCORE 
We investigated the usefulness of an aggregate measure of risk of LVH 
based on the selected genetic susceptibility loci, weighted with the effect 
size on the LVM trait. Following the model presented by De Jager PL et al 
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[81], we selected a subgroup of SNPs from the GWA analysis of LVM trait 
and designed a “weighted genetic risk score” (wGRS). In the wGRS 
algorithm, we used the beta effects from quantitative GWA results, to 
ascertain the strength of the genetic association with each allele. The 
wGRS was calculated by multiplying the number of risk alleles for each 
SNP by the weight for that SNP and then taking the sum across all SNPs, 
according to the following formula:  
𝑤𝐺𝑅𝑆 = ∑(𝑤𝑖 × 𝑋𝑖)
7
𝑖=1
 
where 𝑖 is the SNP, 𝑤𝑖 is the weight of the SNP 𝑖, and 𝑋𝑖 is the number of 
risk alleles (0, 1 or 2). The weight for each SNP is the beta effect for each 
allele, obtained from the linear regression analysis.  
After calculation of wGRS, we tested the distribution of the score in cases 
and controls separately, using a two-sample t-test. The two groups were 
defined as in the case-control logistic analysis, described in paragraph 
3.3.2. All analyses were done using Stata SE (version 11). 
Since a continuous score is difficult to interpret on an individual level, we 
partitioned subjects into different categories of risk. These risk categories 
were created using the means and standard deviations (SD) of wGRS from 
the control samples. The seven categories were defined as ± 0.25, ± 0.75 
and ± 1.25 SDs from the mean, with the extreme categories being < 1.25 
and > 1.25 SDs from the mean. Dividing our score into seven categories 
provided a robust distribution, allowing us to parse out the highest and 
lowest risk groups, while assuring that there were statistically sufficient 
numbers of cases and controls in these extreme categories of interest. We 
used as reference the “category 4”, which contained the wGRS mean of the 
control population. The subjects in this category can be considered as 
20 
 
showing the average risk of the assessed population. Within the case-
control dataset, we calculated the odds ratio for each category.  
3.9  STATISTICAL SOFTWARE 
3.9.1 PLINK 
PLINK (version 1.07) is a free, open-source, whole genome association 
analysis toolset, designed to perform a range of basic, large-scale analyses 
in a computationally efficient manner [73]. PLINK was written in C/C++ 
language. The focus of PLINK is purely on analysis of genotype/phenotype 
data. PLINK provides a simple way to handle large GWAS datasets, 
assesses confounding due to stratification and nonrandom genotyping 
failure and to produce a range of other summary statistics, performs a 
variety of standard association tests on very large datasets in populations 
or families, for disease or quantitative outcomes, allowing for covariates, 
haplotipic tests, etc. PLINK is being developed by Shaun Purcell at the 
Center for Human Genetic Research, Massachusetts General Hospital, and 
the Broad Institute of Harvard & MIT, with the support of others 
(http://pngu.mgh.harvard.edu/purcell/plink). 
3.9.2 Eigensoft 
The EIGENSOFT package (version 3.0 for Linux platform, Department of 
Genetics, Harvard Medical School, Boston, USA) uses PCA to correct for 
population stratification in medical association studies (EIGENSTRAT) [74] 
and to detect and analyze population structure (SMARTPCA) [75]. It 
combines functionality from population genetics methods and 
EIGENSTRAT stratification correction method. The EIGENSTRAT method 
uses PCA to explicitly model ancestry differences between cases and 
controls along continuous axes of variation. The method produces several 
uncorrelated variables from a data matrix containing observation across a 
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number of potentially correlated variables; in the PCA model of ancestry 
detection, the observations are the individuals and the potentially correlated 
variables are the markers. The resulting correction is specific to a candidate 
marker’s variation in frequency across ancestral populations, minimizing 
spurious associations while maximizing power to detect true associations. 
The EIGENSOFT package has a built-in plotting script and supports multiple 
file formats and quantitative phenotypes 
(http://genepath.med.harvard.edu/~reich/Software.htm). 
3.9.3 SHAPEIT2  
SHAPEIT2 is a fast and accurate method for estimation of haplotypes 
(aka phasing) from genotyping or sequencing data [76]. It takes as input a 
set of genotypes and a genetic map, and produces as output, either a 
single set of estimated haplotypes, or a haplotype graph that 
encapsulates the uncertainty about underlying haplotypes 
(https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html). 
3.9.4 Minimac 
Minimac (2012-11-16 version) is a low memory, computationally 
efficient implementation of the MaCH algorithm for genotype 
imputation [77]. MaCH is a Markov Chain Haplotyping software 
package for haplotype estimation and genotype imputation 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html). Minimac 
is designed to work on phased genotypes and can handle very large 
reference panels with hundreds or thousands of haplotypes. It provides 
imputation results as probabilistic calls and not as discrete genotypes. 
These probabilistic genotype calls should not be converted into discrete 
genotypes, as that can result in a substantial loss of information [80]. 
Imputed allele count for each allele can conveniently be tested for 
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association with phenotypic traits using appropriate software, such as 
Mach2qtl (http://genome.sph.umich.edu/wiki/Minimac). 
3.9.5 Mach2qtl 
Mach2qtl (V1.1.2) software performs quantitative trait association analysis 
based on allele dosages or genotype probabilities inferred from imputation 
software [80]. Mach2qtl was developed by Goncalo Abecasis at the 
University of Michigan (http://www.sph.umich.edu/csg/yli/software.html).  
3.9.6 Stata SE 
Stata SE (version 11) is a commercial data analysis and statistical 
software, created in 1985 by “StataCorp” for managing, analyzing, and 
graphing data. Stata SE is used for analysis of large databases 
(http://www.stata.com). 
3.9.7 R 
R (version 2.14.1, copyright 2011, The R Foundation for Statistical 
Computing) is a free language and environment for statistical computing 
and graphics. It is a GNU project (http://www.gnu.org) which is similar to 
the S language and environment, developed at Bell Laboratories (formerly 
AT&T, now Lucent Technologies) by John Chambers and colleagues. R 
can be considered as a different implementation of S. R provides a wide 
variety of statistical (linear and nonlinear modeling, classical statistical 
tests, time-series analysis, classification, clustering, etc.) and graphical 
techniques; it is highly extensible and presents some packages 
implementing statistical methods and algorithms for the analysis of genetic 
data and for related population genetics studies (http://www.r-project.org). 
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3.9.8 Locuszoom 
LocusZoom is designed to facilitate viewing of local association results 
together with useful information about a locus, such as the location and 
orientation of the genes it includes, linkage disequilibrium coefficients and 
local estimates of recombination rates [ 82 ]. LocusZoom provide plot 
summaries of genome-wide scan interactively. LocusZoom allows for quick 
visual inspection of the strength of association evidence, the extent of the 
association signal and linkage disequilibrium (LD), and the position of the 
associated SNPs relative to genes in the region. LocusZoom plots provide 
an option to size the data points relative to sample size and can display 
functional annotation. LocusZoom was written in R using the grid and 
lattice graphics packages and runs within a Python wrapper 
(http://csg.sph.umich.edu/locuszoom).
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4  RESULTS 
The result section is composed by: 
1. quality controls; 
2. descriptive statistics of the cohort; 
3. genotype-phenotype association with LVM quantitative trait; 
4. genotype-phenotype case-control analysis; 
5. aggregation of findings into a weighted genetic risk score.  
4.1 QUALITY CONTROLS 
One thousand and twenty-nine subjects underwent quality control (QC) of 
genetic data.  
Six DNA samples were excluded for low call rate (< 98%) and 8 subjects for 
reduced or increased proportion of heterozygous genotypes. No sex 
mismatches were identified.  
Using genome-wide IBD estimation, we identified and removed from the 
analysis 2 duplicated and 42 related subjects (34 first-degree and 8 
second-degree).  
In order to identify individuals with large-scale differences in ancestry, we 
assessed the population stratification within the data using the principal 
component analysis. We removed 10 outliers defined as individuals that 
exceed 6 standard deviations from the whole sample along any of the 
principal components. Results for the first two PCs are described in figure 
1. 
Figure 2 shows the subjects’ flow from the recruitment to the pre-analysis 
quality control steps. After quality control the final sample is composed of 
966 subjects (633 males and 333 females).  
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Markers were filtered for call rate (threshold at 0.99) and MAF (threshold at 
0.01), leaving 458,953 SNPs, in common between the two genotyping 
array.  
These SNPs were used for imputation. After imputation, markers were 
filtered for minor allele frequency (threshold at 0.99), and for imputation 
quality (threshold of Rsq at 0.8), leaving 7,239,388 SNPs for the 
association analysis. 
4.2 SAMPLE CHARACTERISTICS 
The clinical characteristics of the 966 patients enrolled in the study are 
reported in table 2. Study participants were essential hypertensive white 
Caucasians and included 333 women (34.5%). Age averaged 47.8 years 
(SD ± 9.0); average ( SD) SBP and DBP were 154.8 ± 12.4 mmHg and 
100.1 ± 8.0 mmHg, respectively. The mean LVMh2.7 observed was 44.5 
g/m2.7 (SD  10.0). LVMh2.7 distribution is shown in figure 3 and LVMh2.7 
distribution according to gender is shown in table 3. To assess statistical 
difference in mean LVMh2.7 between males and females, analysis of 
variance (ANOVA) was performed, as implemented in StataSE. LVMh2.7 is 
not significantly different between males and females (p-value = 0.3).  
For the case-control analysis, we divided the sample according to LVM 
values. As described in the Materials and Methods section, we defined as 
case a subject with LVM ≥ 52 g/m2.7 for women and ≥ 56 g/m2.7 for men, 
and as control a subjects with LVM in normal range (≤ 44 g/m2.7 for women 
and ≤ 48 g/m2.7 for men). We excluded from the analysis the subjects with 
mildly abnormal LVM (LVM 45-51 g/m2.7 in women and 49-55 g/m2.7 in 
men). The number of subjects in each group according to their LVM values, 
and their clinical parameters are shown in table 4. Table 5 shows the 
characteristics of the two groups (cases and controls). To assess statistical 
difference in mean LVMh2.7 and in the other clinical characteristics between 
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cases and controls, analysis of variance (ANOVA) was performed, as 
implemented in StataSE; p-values of comparison are reported in table 5. 
Case and control subjects were similar for serum creatinine, uNa24h, HR, 
glycaemia, and uK24h. On the contrary, SBP, DBP, and BMI were 
significantly higher in cases than in controls (p-value < 0.0001); sPRA was 
slightly higher in cases than in controls (p-value < 0.05). Age also was 
slightly different between cases and controls although no evidence exists 
that a difference in age could affect the evaluation of cardiac mass. 
4.3 RESULTS OF QUANTITATIVE TRAIT ASSOCIATION 
ANALYSIS 
A linear regression analysis was performed on LVMh2.7, adjusting for the 
covariates mentioned in paragraph 3.7. This analysis had the aim to identify 
the loci in the genome significantly associated with LVM phenotype. 
Although no SNPs achieved genome wide significance for association with 
LVM (p-values < 5x10-8), we considered SNPs with p-values ≤ 10-5 as 
suggestive. The choice of this p-value threshold was supported by the q-q 
plot (Figure 4). The plot displays deviation from the null distribution only in 
the upper tail, which corresponds to SNPs with the stronger evidence of 
association. SNPs p-value deviated above the distribution reference line, at 
a level ≤ 10-5. In order to exclude redundant findings, we filtered out SNPs 
that were in linkage disequilibrium with each other (r2 ≥ 0.8); we also 
excluded SNPs mapping in desert regions. According to the threshold and 
to these filters, we selected 85 SNPs (table A2, figure 5). Among these, we 
identified 14 SNPs lying in genes previously associated to LVM (table 6): 
rs12369523 in Kinase Suppressor of Ras 2 (KSR2) gene; rs35996865 in 
Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) gene; 
rs78633628 in WW Domain Containing Oxidoreductase (WWOX) gene; 
rs17068332 and rs76156580 in CUB and Sushi multiple domains protein 1 
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(CSMD1) gene; rs183544012 in Calcium Channel Voltage-Dependent L 
Type Alpha 1D Subunit (CACNA1D) gene; rs10863888 in TNF Receptor-
Associated Factor 5 (TRAF5) gene; rs6590636 in Contactin 5 (CNTN5) 
gene; rs79910493 in Insulin-Like Growth Factor (IGF1) gene; rs13023211 
in Fidgetin (FIGN) gene; rs9284436 in Hyperpolarization Activated Cyclic 
Nucleotide Gated Potassium Channel 2 (HCN2) gene; rs76472108 in 
Regulator Of G-Protein Signaling 7 (RGS7) gene; rs2288696 in Fibroblast 
Growth Factor Receptor 1 (FGFR1) gene; and rs7137607 in SRY sex 
determining region Y-box 5 (SOX5) gene. Figure 6 shows regional plots for 
the described genes. 
Figure 7 shows LVM average values according to genotypes of the most 
significant SNPs. The derivative alleles at some of the significant SNPs are 
very rare in the European ancestry population (1000 Genomes Phase 3 
data, http://browser.1000genomes.org/index.html) and in our cohort. They 
are allele C at rs78633628 (WWOX gene), T at rs183544012 (CACNA1D 
gene), T at rs79910493 (IGF1 gene), C at rs76472108 (RGS7 gene), and A 
at rs76156580 (CSMD1 gene). Due to the low frequency, the homozygous 
genotypes for the rare alleles were very rare as well, and were not present 
in our cohort that has a limited size. This justifies the very high beta effect 
linked to these alleles, as shown in table 6.  
The identified polymorphisms map in intronic regions of the mentioned 
genes, except for rs35996865, that maps 532 bases upstream of the 
ROCK1 gene. We investigated if the variant maps to the promoter region of 
ROCK1, through Variant Effect Predictor tool of Ensembl database 
(http://grch37.ensembl.org/Homo_sapiens/Tools/VEP) [ 83 ], TRANSFAC® 
database [ 84 ] and UCSC database (http://genome.ucsc.edu/) [ 85 ]. 
According to all the databases, the variant lies in the promoter region of the 
gene (figure 8), that spans ≈ 1200 bp upstream the transcription initiation 
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site. The database analysis suggests several possible cis DNA elements 
such as AP-1, Sp1, and Oct-1 in the promoter region [86]. 
4.4 RESULTS OF CASE-CONTROL ASSOCIATION 
ANALYSIS 
The aim of the case-control analysis was to identify the risk alleles 
associated with increased LVM. We performed a logistic regression 
analysis on the 14 most interesting results of the quantitative trait analysis 
(table 6). The logistic regression was performed adjusting for ancestry PCs, 
sex, SBP, DBP, serum creatinine, uNa24h, sPRA, BMI, HR, and 
echocardiography operator.  
All SNPs associated with LVM in the linear regression showed a significant 
association with LVM (p-value < Bonferroni’s threshold 3.6x10-3), except for 
rs79910493 and rs76472108, showing that the carriers of the risk alleles 
have an odds ratio higher than 1 to have increased LVM, i.e. to be cases 
respect to controls (table 7). 
As for the quantitative analysis some odds ratios are very high, because of 
the absence of individuals with homozygous genotype of minor alleles. For 
WWOX variant the OR was not calculable because no cases with 
homozygous genotype of the C allele exist: cases are all carriers of the 
homozygous risk allele genotype TT. 
4.5 WEIGHTED GENETIC RISK SCORE 
We defined a weighted genetic risk score using the effect size of the risk 
allele (beta value of the linear regression analysis) to account for the 
strength of the genetic association with each allele. We calculated the 
wGRS including alleles of seven genes (ROCK1, IGF1, CACNA1D, 
FGFR1, TRAF5, SOX5, and KSR2) that are chosen for their functional role 
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in cardiac hypertrophy pathway or LVM determination, supported by data 
from the literature. The weight of each risk allele was calculated as function 
of its genotypic effect size (beta) from the linear GWA analysis (table 8). 
4.5.1 Distribution of wGRS in cases and controls 
The distribution and mean of the wGRS was plotted separately for cases 
and controls (figure 9) and compared using a two-sample t-test. We defined 
as case a subject with LVM ≥ 52 g/m2.7 for women and ≥ 56 g/m2.7 for men, 
and as control a subjects with LVM in normal range (≤ 44 g/m2.7 for women 
and ≤ 48 g/m2.7 for men). Using this model, cases had mean genetic risk 
score of 0.990.26, while controls 0.770.24 (two sample t test p-value < 
0.00001) (table 9).  
4.5.2 Partitioned wGRS 
To describe the difference in the distribution of wGRS between cases and 
controls we partitioned the subjects by defining risk categories; these 
categories are created using the mean and standard deviation (SD) from 
the control subjects. The seven categories were defined as  0.25,  0.75, 
and  1.25 SDs from the mean, with the extreme categories being < 1.25 or 
> 1.25 SDs from the mean. We used as reference the category 4, which 
contains the mean of the control population. This category 4 approximated 
the group of subjects with an average risk of LVM increase. Six subsequent 
categories (1-3 and 5-7) were defined by the subjects found in increasing 
intervals of wGRS (table 10, figure 10). The major percentage of control 
subjects (≈ 19.4%) was in category 3, while the majority of the cases (≈ 
35.44%) were located in the risk category 7, showing a higher genetic 
susceptibility risk for LVH. 
Within the case-control dataset, we fitted a single logistic regression 
analysis, to study the association of wGRS with risk of developing LVH. 
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Thus we calculated the odds ratio (OR) for each category, taking the 
category 4 as reference (table 11). We could not consider results of the 
statistics as reliable on the categories 1, 2, and 3, as their p-value was not 
significant, whereas subjects in categories 5, 6 and 7 (i.e. those with the 
highest wGRS) had 2.22, 4.30 and 5.34 times increased odds of 
developing LVH, respectively, compared with subjects in category 4. The 
LVM distribution according to risk categories is reported in figure 11 (beta 
1.78, p-value 5.03x10-27). 
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Table 2 Characteristics of the subjects analyzed.  
Characteristics Total sample (n=966) 
Sex, M/F 633/333 
Age, years 47.8±9.0 
LVMh2.7, g/m2.7 44.5±10.0 
SBP, mmHg 154.8±12.4 
DBP, mmHg 100.1±8.0 
Heart rate, b.p.m. 75.4±10.0 
Urine sodium, mEq/24 h 148.0±51.0 
Urine potassium, mEq/24 h 56.5±20.3 
sPRA, ng/mL/h 1.4±1.1 
Glycaemia, mg/dl 89.8±11.0 
Serum creatinine, mg/dl 0.9±0.2 
BMI, kg/m2 27.2±3.6 
 
Values are reported as meanstandard deviation. Glossary: LVMh
2.7
, left 
ventricular mass indexed for height
2.7
; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; b.p.m, beats per minute; sPRA, sitting plasma renin activity; BMI, 
body mass index. 
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Table 3 LVMh2.7 distribution according to gender. 
 
 
LVMh
2.7 
was evaluated as g/m
2.7
. 
 
Table 4 Reference limits of LVM according to gender (from Lang RM et al 
[18]) and characteristics of analyzed subjects for each class. 
Sample N mean LVMh2.7 SD min LVMh2.7 max LVMh2.7 
All 966 44.5 10.0 20.0 82.4 
Males 633 45.4 10.0 20.5 82.4 
Females 333 42.7 9.8 20.0 80.7 
 Women 
 Reference 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
LVM, g/m2.7  18-44 45-51 52-58 ≥ 59 
N subjects 198 74 43 18 
Age, years 48.38.9 47.38.8 48.97.9 50.46.2 
LVM, g/m2.7 36.25.1 47.62.3 55.22.1 65.05.9 
SBP, mmHg 154.111.6 159.015.7 161.615.5 159.415.1 
DBP, mmHg 98.58.2 101.76.8 100.96.1 101.46.5 
HR, b.p.m. 75.39.6 75.310.3 76.910.2 73.79.8 
uNa, mEq/24 h 136.650.4 142.649.3 147.636.0 124.238.2 
uK, mEq/24 h 52.415.8 53.115.4 54.310.1 56.718.4 
sPRA, ng/mL/h 1.31.2 1.91.3 1.61.0 1.70.9 
Glycemia, mg/dl 87.89.9 90.212.4 87.610.2 87.88.1 
Serum crea, mg/dl 0.830.15 0.880.16 0.820.15 0.840.24 
BMI, kg/m2 25.43.6 28.14.7 26.83.5 28.64.0 
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Values are reported as meanstandard deviation. Glossary: LVMh
2.7
, left 
ventricular mass indexed for height
2.7
; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HR, heart rate; b.p.m beats per minute; uNa, urine sodium; uK, 
urine potassium; sPRA, sitting plasma renin activity; crea, creatinine; BMI, body 
mass index. 
 
 
 Men 
 Reference 
range 
Mildly 
abnormal 
Moderately 
abnormal 
Severely 
abnormal 
LVM, g/m2.7  20-48 49-55 56-63 ≥64 
N subjects 417 119 67 30 
Age, years 47.39.3 47.59.3 47.97.7 52.29.2 
LVM, g/m2.7 39.85.8 51.52.2 59.32.1 69.14.9 
SBP, mmHg 152.610.1 155.012.9 156.112.8 164.416.6 
DBP, mmHg 99.07.4 102.48.9 102.58.4 105.69.4 
HR, b.p.m. 75.79.8 76.29.2 71.210.3 75.910.8 
uNa, mEq/24 h 150.352.7 162.755.1 154.546.3 146.632.0 
uK, mEq/24 h 59.624.2 57.219.7 57.417.4 49.412.3 
sPRA, ng/mL/h 1.31.1 1.51.3 1.51.0 1.71.0 
Glycemia, mg/dl 90.511.3 91.511.1 90.711.5 87.86.4 
Serum crea, mg/dl 0.950.16 0.970.16 0.970.14 0.970.12 
BMI, kg/m2 27.43.0 27.83.5 27.92.6 30.73.6 
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Table 5 Characteristics of the subjects analyzed in cases and controls. 
 
Values are reported as meanstandard deviation. P-values of comparison among 
groups are reported. Glossary: LVMh
2.7
, left ventricular mass indexed for height
2.7
; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; b.p.m., beats per 
minute; sPRA, sitting plasma renin activity; BMI, body mass index; NS, non 
significative. 
Characteristic 
  Cases 
(n=158) 
Controls 
(n=615) 
p-value 
Sex, M/F   97/61 417/198 NS 
Age, years   49.3 ± 8.0 47.6 ± 9.1 3.53E-02 
LVMh2.7, g/m2.7   60.7 ± 6.0 38.6 ± 5.8 < 0.0001 
SBP, mmHg   159.5 ± 14.8 153.1 ± 10.6 < 0.0001 
DBP, mmHg   102.5 ± 8.0 99.0 ± 8.0 < 0.0001 
Heart rate, b.p.m.   73.9 ± 10.5 75.6 ± 9.7 NS 
Urine sodium, mEq/24 h   147.7 ± 41.0 145.9 ± 52.3 NS 
Urine potassium, mEq/24 h   54.9 ± 15.1 57.2 ± 22.1 NS 
sPRA, ng/mL/h   1.6 ± 1.0 1.3 ± 1.1 1.92E-03 
Glycaemia, mg/dl   89.0 ± 10.0 89.6 ± 11.0 NS 
Serum creatinine, mg/dl   0.9 ± 0.2 0.9 ± 0.2 NS 
BMI, kg/m2   28.2 ± 3.5 26.7 ± 3.4 < 0.0001 
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Table 6 Functional SNPs associated to left ventricular mass (LVMh2.7) in linear regression. 
SNP Chr Position (bp) Gene Location 
Risk/other 
Alleles 
Allele 
freq 
Beta SE p-value 
rs12369523 12 118309008 KSR2 intron A/G 0.57 2.25 0.43 1.37E-07 
rs35996865 18 18692344 ROCK1 upstream G/T 0.3 2.33 0.46 3.17E-07 
rs78633628 16 78971380 WWOX intron T/C 0.99 10.95 2.46 8.66E-06 
rs17068332 8 3833181 CSMD1 intron C/T 0.88 2.63 0.63 3.05E-05 
rs183544012 3 53747902 CACNA1D intron T/C 0.02 6.46 1.57 3.93E-05 
rs10863888 1 211502769 TRAF5 intron G/A 0.59 1.71 0.42 4.23E-05 
rs6590636 11 100047729 CNTN5 intron A/C 0.44 1.71 0.42 4.30E-05 
rs79910493 12 102843754 IGF1 intron T/C 0.02 5.94 1.46 4.60E-05 
rs13023211 2 164504320 FIGN intron A/G 0.86 2.55 0.63 4.85E-05 
rs9284436 19 607108 HCN2 intron C/T 0.43 1.75 0.44 5.89E-05 
rs76472108 1 241304791 RGS7 intron C/G 0.02 6.07 1.54 7.71E-05 
rs76156580 8 4474130 CSMD1 intron A/C 0.01 8.53 2.16 7.98E-05 
rs2288696 8 38286225 FGFR1 intron G/A 0.81 2.06 0.53 8.79E-05 
rs7137607 12 23778584 SOX5 intron A/C 0.55 1.61 0.41 9.63E-05 
 
LVMh
2.7
 association was evaluated using a linear regression analysis under an additive model, adjusted for ancestry PCs, sex, 
SBP, DBP, serum creatinine, uNa24h, sPRA, BMI, HR, and ECG operator. Allele frequency and Beta effect are referred to risk 
allele. To retrieve information about SNPs and their genomic context (the nearest gene) we used the hg19 assembly (National 
Center for Biotechnology Information 37). Glossary: SNP, Chr, chromosome; bp, base pair; and SE, standard error.  
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Table 7 Functional SNPs associated to left ventricular mass (LVMh2.7) in case-control analysis. 
SNP Chr 
Position 
(bp) 
Gene Location 
Risk/other 
Alleles 
Allele 
freq 
OR p-value 95% CI 
rs12369523 12 118309008 KSR2 intron A/G 0.57 1.7 3.62E-04 1.27-2.27 
rs35996865 18 18692344 ROCK1 upstream G/T 0.3 1.7 5.02E-04 1.26-2.30 
rs78633628 16 78971380 WWOX intron T/C 0.99 /* / / 
rs17068332 8 3833181 CSMD1 intron C/T 0.88 2.46 2.62E-04 1.52-3.99 
rs183544012 3 53747902 CACNA1D intron T/C 0.02 3.92 9.92E-04 1.74-8.83 
rs10863888 1 211502769 TRAF5 intron G/A 0.59 1.99 8.34E-06 1.47-2.69 
rs6590636 11 100047729 CNTN5 intron A/C 0.44 1.81 3.84E-05 1.37-2.41 
rs79910493 12 102843754 IGF1 intron T/C 0.02 2.77 1.10E-02 1.27-6.06 
rs13023211 2 164504320 FIGN intron A/G 0.86 1.86 7.00E-03 1.18-2.94 
rs9284436 19 607108 HCN2 intron C/T 0.43 1.62 1.00E-03 1.22-2.17 
rs76472108 1 241304791 RGS7 intron C/G 0.02 3.72 1.10E-02 1.68-8.24 
rs76156580 8 4474130 CSMD1 intron A/C 0.01 4.62 5.00E-03 1.58-13.54 
rs2288696 8 38286225 FGFR1 intron G/A 0.81 1.73 5.00E-03 1.18-2.54 
rs7137607 12 23778584 SOX5 intron A/C 0.55 1.69 3.23E-04 1.27-2.26 
 
LVMh
2.7
 association was evaluated using a logistic regression analysis under an additive model, adjusted for ancestry PCs, sex, 
SBP, DBP, serum creatinine, uNa24h, sPRA, BMI, HR, and echocardiography operator. Allele frequency and Beta effect are 
referred to risk allele. Glossary: SNP, single nucleotide polymorphism; Chr, chromosome; OR odds ratio; and 95% CI, 95% 
confidence intervals. *not calculable (cases with homozygous genotype of the C allele are missing) 
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Table 8 SNPs that compose the weighed genetic risk score and weights 
assigned to each marker. 
Chr SNP Risk Allele Gene Beta effect (weight) 
12 rs12369523 A KSR2 2.25 
18 rs35996865 G ROCK1 2.33 
3 rs183544012 T CACNA1D 6.46 
1 rs10863888 G TRAF5 1.71 
12 rs79910493 T IGF1 5.94 
8 rs2288696 G FGFR1 2.06 
12 rs7137607 A SOX5 1.61 
 
Glossary: Chr, chromosome; and SNP, single nucleotide polymorphism. 
 
Table 9 Left ventricular mass mean values and weighted genetic risk score 
distribution in cases and controls. 
 
Mean LVM 
(g/m2.7) 
SD number wGRS SD 95% CI 
Controls 38.63 5.83 615 0.77 0.24 0.75 0.79 
Cases 60.71 6.01 158 0.99 0.26 0.95 1.03 
Total 43.15 10.66 773 0.82 0.26 0.80 0.84 
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Table 10 Distribution of subjects in the risk categories defined by the 
weighed genetic risk score. 
Categories Formula Score N (%) controls N (%) cases 
1 mean -1.25 SD ≤ 0.470 61 (9.92) 2 (1.27) 
2 mean -0.75 SD 0.470-0.591 101 (16.42) 6 (3.80) 
3 mean -0.25 SD 0.59-0.713 122 (19.84) 20 (12.66) 
4 (Ref) mean 0.714-0.834 116 (18.86) 16 (10.13) 
5 mean +0.25 SD 0.83-0.955 85 (13.82) 26 (16.46) 
6 mean +0.75 SD 0.956-1.077 54 (8.78) 32 (20.25) 
7 mean +1.25 SD > 1.077 76 (12.36) 56 (35.44) 
TOT  
 
615 (79.56) 158 (20.44) 
 
In the table, for each category, is reported the number and percentage of controls 
and cases. The frequency is calculated according to the total number of individuals 
for each status. 
 
Table 11 Weighed genetic risk score scores and odds ratios of left 
ventricular mass in each risk category. 
wGRS category Controls Cases OR p-value 
1 61 2 0.24 0.06 
2 101 6 0.43 0.09 
3 122 20 1.19 0.63 
4 116 16 1 (reference) - 
5 85 26 2.22 0.022 
6 54 32 4.30 < 0.0001 
7 76 56 5.34 < 0.0001 
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Figure 1 Principal component plot.  
 
 
 
 
 
 
Samples are marked according to ancestry cluster based on genotyping data: 
continental Italy samples in green, Sardinian samples in red and outliers in blue; 
PC principal component. 
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Figure 2 Subjects’ flow from recruitment to pre-analysis quality control 
steps. 
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Figure 3 Histogram of left ventricular mass (LVMh2.7) distribution in the 
analyzed sample (normal curve superimposed); LVMh2.7 was expressed in 
g/h2.7.
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Figure 4 Quantile-quantile plot of single nucleotide polymorphism p-values 
from genome wide association analysis of left ventricular mass (LVMh2.7).  
 
The red line indicates the middle of the first and third quartile of the expected 
distribution of test statistics; the dashed line marks the 95% confidence interval of 
the expected distribution of the test statistics. 
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Figure 5 Manhattan plot of single SNP linear regression test statistics for 
LVMh2.7.  
 
Regression analysis was adjusted for gender, systolic and diastolic blood pressure, 
serum creatinine, urinary sodium 24 h, sitting plasma renin activity, body mass 
index, heart rate, first ten principal components, and echocardiography operator. 
Markers were filtered for imputation quality (Rsq, threshold 0.8) and minor allele 
frequency (threshold 0.01). Results are reported as -log10 (p-value) by genomic 
position chromosomal location. Values for each chromosome are shown in different 
colors. 
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Figure 6 Local Manhattan plot for KSR2 (a), ROCK1 (b), WWOX (c), 
CSMD1 (d), CACNA1D (e), TRAF5 (f), CNTN5 (g), IGF1 (h), FIGN (i), 
HCN2 (j), RGS7 (k), FGFR1 (l), and SOX5 (m) genes. 
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Each circle represents a single nucleotide polymorphism; y-axis is the -log10 LVM 
association p-value, and x-axis represents the physical position on the 
chromosome (build 37, hg 19). The circles are filled with colors according to the 
linkage disequilibrium (LD, r2) between the given SNPs and the lead SNP (purple 
square). 
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Figure 7 Plot of LVM average by KSR2 rs12369523 (a), ROCK1 
rs35996865 (b), WWOX rs78633628 (c), CSMD1 rs17068332 (d), 
CACNA1D rs183544012 (e), TRAF5 rs10863888 (f), CNTN5 rs6590636 (g), 
IGF1 rs79910493 (h), FIGN rs13023211 (i), HCN2 rs9284436 (j), RGS7 
rs76472108 (k), CSMD1 rs76156580 (l), FGFR1 rs2288696 (m), and SOX5 
rs7137607 (n) genotypes of participants.  
 
 
.
52 
 
 
 
  
53 
 
 
 
 
 
 
 
 
 
In each box the number of subjects per genotype is indicated. P-values and Beta 
effects for each variant are reported in table 6. 
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Figure 8 Genomic region of ROCK1 gene on chromosome 18 (a) and region in detail around rs35996865 variant (b) 
(http://browser.1000genomes.org/). 
 
(a) 
(b) 
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Figure 9 Box plot of wGRS average value and distribution in control and in 
case groups.  
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Figure 10 Distribution of percentage of controls (blue) and cases (grey) 
subjects in each risk category defined by wGRS. 
 
The frequency is calculated according to the total number of individuals for each 
status. 
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Figure 11 Box plot of wGRS (a) and LVM (b) distribution for each risk 
categories. 
 
LVMh
2.7
 was expressed in g/h
2.7
. 
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5 DISCUSSION 
We performed a genome wide association analysis in an Italian cohort of 
never treated mild-to-moderate essential hypertensive subjects to search 
for genetic variants predictive of LVM trait. The absence of previous 
antihypertensive treatment, i.e. absence of unpredictable interferences by 
antihypertensive drugs on LVM, is the pivotal characteristic of our cohort to 
warrant a “clean reference phenotype” thus minimizing the “background 
noise” that often represents a bias in genotype-phenotype association 
studies. The antihypertensive treatments commonly used to control blood 
pressure affect cardiac mass, thus the reliability of the findings in 
association studies on cardiac mass in EH must be based on never treated 
EHs [87,88,89].  
Left ventricular hypertrophy is considered as a powerful, independent risk 
factor for cardiovascular disease. Therefore, LVM can be considered not 
only as measures of cardiac structure, but also can offer prognostic 
information for assessing CVD risk [1]. Some evidences have 
demonstrated that regression of LVH is associated with a favorable 
prognosis [12,90]. Given the clinical importance of this trait, it can be useful 
to target intracellular signaling pathways involved in the regulation of LVM. 
In our study, overall we identified 85 SNPs associated to LVM with a 
suggestive p-value < 10-5. Some of the genes in which our best SNPs map, 
ROCK1, IGF1, CACNA1D, FGFR1, TRAF5, SOX5, and KSR2 were 
previously described as having a role in the pathogenesis of cardiac 
hypertrophy. Each of them might play a putative role in determining the 
LVM phenotype as well as other pathophysiological pathways directly or 
indirectly linked to cardiac pathophysiology.  
Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) is a 
downstream mediator of the small GTP-binding protein RhoA. The 
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RhoA/Rho-kinase pathway is now widely known to play important roles in 
many cellular functions, including smooth muscle contraction, motility, 
proliferation, and apoptosis, and its excessive activity induces oxidative 
stress and promotes the development of cardiovascular disease [91]. A 
beneficial effect of long-term inhibition of Rho-kinase has been 
demonstrated in animal models for the treatment of various cardiovascular 
diseases [ 92 ]. In the vascular smooth muscle cells, the activation of 
RhoA/Rho-kinase pathway modules the expression of hypertrophy genes 
(PAI-1, MCP-1, etc.) [91] (figure 12). In vivo animal studies, using ROCK 
inhibitors, Y27632 and fasudil, suggested a role for ROCK in mediating 
cardiac hypertrophy and remodeling [ 93 ]. Shi J. and colleagues 
demonstrated that ROCK1 deletion prevented or attenuated a variety of 
pathological characteristic of Gq mice (cardiac hypertrophy animal model), 
such as induction of hypertrophic markers [94].  
Insulin-Like Growth Factor 1 (IGF1) is a neurohumoral factor, member of a 
family of proteins involved in mediating growth and development. In 
cardiomyocytes, IGF1 activates multiple downstream signaling pathways 
for controlling cell death, metabolism, autophagy, differentiation, 
transcription, and protein synthesis [ 95 ]. These pathways involve the 
extracellular signal-regulated kinase (ERK) cascade, associated with the 
pro-hypertrophic and pro-survival actions [95], and the phosphatidylinositol-
3 kinase (PI3K)/Akt pathway, associated with physiological cardiac 
hypertrophy [ 96 , 97 ]. Moreover, (PI3K)/Akt signaling axis is critical for 
transducing physiological and adaptive hypertrophy, but also the 
overstimulation of the pathway can result in pathological hypertrophy [98]. 
In addition, the two pathways activated by IGF1 in cardiomyocytes (ERK 
and Akt pathway) crosstalk with each other leading to hypertrophy [98].  
Calcium Channel Voltage-Dependent L-Type Alpha 1D Subunit 
(CACNA1D) gene encodes a member of the alpha-1 subunit family of 
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voltage-dependent calcium channels, also known as dihydropyridine-
sensitive receptor (DHPR). These calcium channels mediate the entry of 
calcium ions into excitable cells and are involved in a variety of calcium-
dependent processes, including cardiac and vascular smooth muscle 
contraction, hormone and neurotransmitter release, gene expression, cell 
motility, cell division, and cell death [ 99 ]. CACNA1D has a role in 
hypertrophic cardiomyopathy, in the pacemaker activity of the hearth and in 
atrial fibrillation [100,101].  
The pathways activated by IGF1 lead also to Ca2+ influx and, in 
cardiomyocytes, IGF1 and CACNA1D protein are in the same cascade of 
Ca2+ signaling, leading to transcriptional upregulation and cardiac 
hypertrophy [95,98]. IGF1 and CACNA1D are in the same pathway of 
hypertrophic cardiomyopathy (HCM), a primary myocardial disorder with an 
autosomal dominant pattern of inheritance, characterized by hypertrophy of 
left ventricle. IGF-1, with other molecules (such as such as ACE1, 
angiotensin II, TGF-β, TNF-α, IL-6, and endothelin) increases the entrance 
of calcium into the cells, through L-type Ca2+ voltage-gated channels, as 
CACNA1D, and the activation of transcriptional pathways leads to the 
diverse histological and structural phenotypes of HCM including cardiac 
hypertrophy, interstitial fibrosis, and myocyte disarray [100] (Figure 13).  
Variants at IGF1 and CACNA1D genes have been also identified as 
hypertension susceptibility variants in two genome-wide association studies 
in Chinese cohorts [99,102]. 
Fibroblast Growth Factor Receptor 1 (FGFR1) gene encodes a receptor of 
fibroblast growth factors (FGFs). FGFs are secreted proteins with diverse 
functions mainly in development and metabolism. Some FGFs, such as 
FGF2, FGF16, FGF21, and FGF23 are secreted from the heart, are 
referred to as cardiomyokines and have an important role in heart function. 
In particular, FGF2 promotes cardiac hypertrophy and remodeling by 
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activating MAPK signaling; FGF16 and FGF21 may prevent cardiac 
hypertrophy and remodeling through the same signaling pathway; FGF23 
promotes cardiac hypertrophy and remodeling through calcineurin/NFAT 
pathway. The biological effects of FGF2, FGF16, FGF21, and probably 
FGFR23 in the myocardium are mediated by the high-affinity tyrosine 
kinase receptor FGFR1, the major FGF receptor in the heart. These 
findings support the pathophysiological roles of FGFs and their receptors in 
the heart [103]. 
TNF Receptor-Associated Factor 5 (TRAF5) gene encodes for a signal 
transducer, member of the tumor necrosis factor (TNF) receptor family. In 
vivo experiments in TRAF5-deficient mice showed that TRAF5 deficiency 
aggravated cardiac hypertrophy, fibrosis and inflammation, and markedly 
promotes the activation of MEK-ERK1/2 pathway. Therefore, TRAF5 is an 
intrinsic suppressor of cardiac hypertrophy through the negative regulation 
of the MEK-ERK1/2 pathway. This signaling pathway plays a role in the 
progression of cardiac hypertrophy through the phosphorylation of 
intracellular targets, including transcription factors, under stress stimuli 
[104].  
Kinase Suppressor of Ras 2 (KSR2) functions as an essential scaffolding 
protein to coordinate the activation of MEK-ERK cascade in response to 
calcium signals [105]. Evidence from in vitro studies, revealed that KSR2 is 
a relevant effector of Ca2+-signaling and depletion of KSR2 significantly 
impaired ERK activation [105]. As previously mentioned, several studies 
provide strong evidence for an important role of the MEK-ERK cascade in 
the heart: a protective anti-apoptotic function as well as a hypertrophic 
function [106].  
Three of the identified genes, TRAF5, IGF1, and KSR2, activate MEK-ERK 
cascade, well known as involved in the pathophysiological process of 
cardiac hypertrophy [106]. 
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SRY sex determining region Y-box 5 (SOX5) gene encodes a transcription 
factor. Its expression is modulated by nitric oxide (NO) and guanylyl 
cyclase after stress in endothelial cells [107]. Endothelial NO levels are 
significantly correlated with LVM [108]. In addition, SOX5 plays a pivotal 
role in the expression of the muscle L-type Ca2+ channel, as CACNA1D 
[109]. Variation in the expression of these channels is associated with 
cardiac hypertrophy [110]. 
We also identified other SNPs significantly associated to LVM, in genes 
with a less clear or direct involvement in heart function: WWOX, RGS7, 
CSMD1, CNTN5, FIGN, and HCN2. Some of these genes have been 
identified as hypertension susceptibility genes in Han Chinese (WWOX 
[111]) and in two case-control studies in Korean cohorts (CSMD1 [112]). 
WWOX has been also associated to LV wall thickness [9]; RGS7 is 
associated with cardiac disease, including hypertrophy [113], as HCN2 
[114]; CNTN5 has been associated with atrial fibrillation and heart failure 
[115]; FIGN is involved in blood pressure regulation [116] and with pulse 
pressure and mean arterial pressure [117]. Table A3 reports more details 
about their functional role in experimental setting. 
The polymorphisms that are found significantly associated to LVM as 
quantitative trait were also tested for their association to LVM with a case-
control approach. The odds ratios obtained were statistically significant 
(except for two variants). Nevertheless as for most of the complex traits, the 
observed odds ratios are modest (except for those biased by the absence 
of homozygous risk genotypes), so their relevance for a clinical use is 
uncertain. Thus, the possibility to combine more variants in a global genetic 
risk score could be interesting and could add relevance to the results. 
Further assessment of this score is therefore warranted, and 
implementation with newly discovered LVM related loci, and with non-
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genetic susceptibility factors, such as environmental risk factors, could 
improve the predictive ability of the algorithm.  
Genome-wide linkage and association studies have been performed by 
different groups to identify genetic loci associated to LVM. In a whole 
genome linkage study on hypertensive families, three regions (10q23.1, 
12q14.1, 17p13.3) were found to approach suggestive evidence of linkage 
for LVH [57]. A GWAS on Koreans reported a significative correlation 
between the skeletal muscle Ca2+ channel protein RYR1 on chromosome 
19 and ECG-LVH [58]. The HyperGEN study identified a polymorphism in 
KCNB1 gene associated with LVM using a GWA approach [9]. A large 
meta-analysis identified loci associated with left ventricular structure on the 
solute carrier family 35, member F1 (SLC35F1) gene, chromosome 6 open 
reading frame 203 (C6orf203), and phospholamban (PLN) gene [59]. 
Recently, Barve RA et al identified eleven SNPs with a suggestive 
association with left ventricular mass trait, in a comparative study between 
M-mode and 2D echocardiography and between raw LVM and body 
surface area-indexed LVM. One SNP lies in CDH13 gene was confirmed in 
all the four measurements [60]. None of the genes recognized by these 
studies achieves a p-value < 10-5 in our study. Candidate genes studies 
have been widely used before the advent of GWAS to explore the genetic 
basis of LVM. The genes identified with this approach were: angiotensin-
converting enzyme (ACE) [46,47,48,49], aldosterone synthase (CYP11B2) 
[50], insulin-like growth factor (IGF1) [51], neuropeptide Y (NPY) [52], 
guanine nucleotide-binding protein 3 (GNB3) [53], endothelial nitric oxide 
synthase (eNOS) [54], peroxisome proliferator-activated receptor-alpha 
(PPARA) [55], and centlein centrosomal protein (CNTLN) [56] genes. 
Neither these genes achieves a significant p-value in our study, except 
IGF1.
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Figure 12 Rho/Rho-kinase signaling in endothelial cells and vascular smooth muscle cells (VSMC) interaction. In 
red is highlighted the pathway that enhances expression of hypertrophic genes. 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Ref. 91.
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Figure 13 Nuclear calcium signaling in cardiomyocytes. 
 
DHPR is a calcium channel (CACNA1D is a member of this family of calcium 
channels) that mediates the entry of calcium ions into cardiomyocytes. IGF1R 
activation by IGF1 binding leads to nuclear Ca
2+
 signals and to expression of 
genes associated to development of cardiomyocyte hypertrophy. Abbreviations: 
RyR, ryanodine receptor; ECC, excitation–contraction coupling; PLC, 
phospholipase C; DHPR, dihydropyridine receptor. Adapted from Ref. 99 and 108. 
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6 CONCLUSION 
Our GWAS allowed us to pinpoint genes whose role in heart function 
and/or cardiac hypertrophy has been demonstrated in previously 
publications by different authors. Moreover, we highlighted the usefulness 
of an aggregate measure of risk of LVH to discriminate high risk subjects. 
However, the present results must be interpreted within the context of the 
following potential limitations and perspectives. 
We did not reach a Bonferroni’s significance level probably due to a limited 
sample size. However, the phenotypic homogeneity of our cohort and the 
absence of previous antihypertensive treatment are prerequisites for the 
identification of true genetic effects. 
GWAS are exploratory analyses and their replication represents the gold 
standard for assessing whether the findings are true-positive. In the present 
study, an independent cohort of hypertensive patients with LVM phenotype 
and enrolled with similar criteria was not available for replication.  
GWA studies may establish significant genomic regions, though the real 
cause-effect relationship remains difficult to clarify. Moreover it often 
happens, as in our study, that significant SNPs map in non-coding regions, 
making it difficult to explain their causative role.  
These limitations should not reduce the relevance of the genes identified 
and confirmed by previously published papers.  
Future perspectives of this study should be: 
1. Replication of the GWAS findings in independent cohorts to further 
confirm the genomic regions as true positives and to identify the putative 
genetic variant with respect to LVM.  
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2. Assessment in independent samples of the prediction ability (sensibility 
and specificity) of wGRS to correctly classify true positives (i.e. subjects 
with high risk of developing LVH) and true negatives (i.e. subjects with low 
risk) according to their genetic background. 
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APPENDIX  
Table A1: Clinical research centers that recruited patients for the study. 
Recruitment center 
Number of 
subjects 
Department of Medicine and Hypertension Centre 
University of Catania 
31 
Department of Clinic and Experimental Medicine, 
Cardiovascular Disease Unit, University of Catanzaro 
‘Magna Graecia’ 
41 
Division of Internal Medicine, ASL Isernia 46 
Department of Internal Medicine and Public Health, 
University of L’Aquila 
44 
Department of Internal Medicine, University Federico II, 
Napoli 
29 
Department of Medical and Surgical Sciences, University 
of Padova 
31 
Department of Clinical And Experimental Medicine, 
University of Padova  
11 
Department of Internal Medicine, University of Pisa 23 
Division of Internal Medicine, ASL Reggio Emilia 8 
Division of Internal Medicine and Hypertension Center, 
S.Giovanni Battista e della Città di Torino Hospital, 
University of Torino 
26 
Joint ASL n.1, AOU Sassari 676 
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Table A2: Association results for LVMh2.7. 
SNP chr 
position 
(bp) 
alleles 
risk 
allele 
freq 
gene location beta SE p-value 
rs7207593 17 66037405 T/C 0.02 KPNA2 intron -13.8 3.52 8.94E-05 
rs78633628 16 78971380 C/T 0.01 WWOX intron -10.95 2.46 8.66E-06 
rs4966230 15 28969573 A/G 0.04 WHAMMP2 intron -7.79 1.56 5.66E-07 
rs2486612 9 99730155 A/G 0.04 HIATL2 intron -6.99 1.47 1.93E-06 
rs9620166 22 23076572 T/C 0.04 IGLV3-17 upstream -6.4 1.59 5.79E-05 
rs17252060 5 53321543 G/A 0.03 ARL15 intron -5.85 1.4 2.89E-05 
rs114996389 3 99379688 T/G 0.03 COL8A1 intron -5.16 1.3 7.02E-05 
rs111739640 1 242430997 C/T 0.06 PLD5 intron -4.41 1.09 5.49E-05 
rs9274407 6 32632832 A/T 0.06 
HLA-
DQB1-AS1 
exon 
(missense) 
-4.27 1.09 8.63E-05 
rs74840030 3 111901099 C/T 0.06 SLC9C1 
exon 
(missense) 
-3.63 0.86 2.63E-05 
rs73853324 3 111887788 G/A 0.07 SLC9C1 
exon 
(missense) 
-3.59 0.85 2.54E-05 
rs76400391 3 111915627 C/T 0.07 SLC9C1 intron -3.58 0.84 2.09E-05 
rs59688356 14 58224134 T/C 0.06 SLC35F4 intron -3.43 0.87 8.00E-05 
rs10167952 2 29809505 G/C 0.12 ALK intron -2.8 0.67 3.17E-05 
rs56096309 10 17877539 A/C 0.2 MRC1 intron -2.65 0.59 6.56E-06 
rs17068332 8 3833181 T/C 0.12 CSMD1 intron -2.63 0.63 3.05E-05 
rs13023211 2 164504320 G/A 0.14 FIGN intron -2.55 0.63 4.85E-05 
rs6007872 22 48897704 A/G 0.13 FAM19A5 intron -2.5 0.63 8.14E-05 
rs9867121 3 114631548 A/C 0.18 ZBTB20 intron -2.38 0.57 2.46E-05 
rs9442871 6 73648263 T/C 0.16 KCNQ5 intron -2.38 0.59 5.21E-05 
rs77732888 15 49088198 A/G 0.16 CEP152 intron -2.31 0.58 7.67E-05 
rs35422477 8 38242712 G/A 0.2 WHSC1L1 upstream -2.08 0.52 7.14E-05 
rs2288696 8 38286225 A/G 0.19 FGFR1 intron -2.06 0.53 8.79E-05 
rs7959200 12 9330417 A/C 0.24 PZP intron -2.04 0.51 5.46E-05 
rs4731960 7 133206438 G/A 0.28 EXOC4 intron -1.97 0.49 6.45E-05 
rs682856 3 174415647 C/T 0.47 NAALADL2 intron -1.76 0.42 2.29E-05 
rs10863888 1 211502769 A/G 0.41 TRAF5 intron -1.71 0.42 4.23E-05 
rs12403576 1 211439571 A/G 0.41 RCOR3 intron -1.67 0.42 6.42E-05 
rs3002258 1 211617397 T/G 0.42 ARPC3P2 downstream -1.64 0.42 8.73E-05 
rs6579841 5 150622225 G/A 0.42 GM2A intron -1.63 0.42 9.70E-05 
rs5930 19 11224265 A/G 0.42 LDLR downstream -1.63 0.42 9.08E-05 
rs784369 1 211558096 A/G 0.42 LINC00467 intron -1.62 0.42 9.91E-05 
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SNP 
chr 
position 
(bp) 
alleles 
risk 
allele 
freq 
gene location beta SE p-value 
rs7137607 12 23778584 C/A 0.45 SOX5 intron -1.61 0.41 9.63E-05 
rs6700747 1 211431105 A/C 0.44 RCOR3 upstream -1.6 0.41 9.79E-05 
rs9646862 2 220233328 C/T 0.55 DNPEP downstream -1.65 0.42 8.02E-05 
rs12198266 6 83743782 T/C 0.55 UBE3D intron -1.66 0.42 8.28E-05 
rs2993503 1 3028987 G/A 0.5 PRDM16 intron -1.67 0.43 9.30E-05 
rs10437924 12 52951208 G/A 0.63 KRT71 upstream -1.7 0.43 8.01E-05 
rs6590636 11 100047729 C/A 0.56 CNTN5 intron -1.71 0.42 4.30E-05 
rs1790650 16 57511069 G/A 0.62 DOK4 intron -1.71 0.44 9.76E-05 
rs9284436 19 607108 T/C 0.57 HCN2 intron -1.75 0.44 5.89E-05 
rs7504272 18 19172917 C/T 0.39 ESCO1 downstream -1.76 0.45 8.58E-05 
rs291785 18 19015831 T/C 0.38 GREB1L intron -1.77 0.43 4.26E-05 
rs6887266 5 13837218 G/A 0.38 DNAH5 intron -1.77 0.45 7.45E-05 
rs56202747 11 89700849 A/G 0.31 TRIM64 upstream -1.78 0.45 8.68E-05 
rs114443041 1 24281021 G/A 0.54 CNR2 intron -1.86 0.39 1.60E-06 
rs6946807 7 146608784 G/A 0.64 CNTNAP2 intron -1.88 0.45 2.83E-05 
rs3825448 13 25145058 C/T 0.75 PSPC1P2 downstream -1.93 0.49 8.42E-05 
rs10166469 2 29829167 C/T 0.76 ALK intron -1.94 0.5 9.49E-05 
rs115299983 21 15199811 G/A 0.69 CNN2P7 nc transcript -1.95 0.45 1.55E-05 
rs7302899 12 118302322 G/A 0.45 KSR2 intron -1.95 0.41 2.24E-06 
rs7642531 3 23842814 A/C 0.77 
UBE2E1-
AS1 
downstream -2.05 0.52 7.71E-05 
rs35910954 15 92581551 A/T 0.79 SLCO3A1 intron -2.06 0.53 8.88E-05 
rs7894754 10 73074310 C/T 0.81 SLC29A3 upstream -2.09 0.53 8.01E-05 
rs1149050 1 31200342 A/G 0.78 
MATN1-
AS1 
downstream -2.11 0.54 9.81E-05 
rs55803951 9 7134281 C/T 0.77 KDM4C intron -2.22 0.52 2.07E-05 
rs1198591 1 98541836 G/C 0.81 NFU1P2 upstream -2.23 0.55 4.27E-05 
rs12369523 12 118309008 G/A 0.43 KSR2 intron -2.25 0.43 1.37E-07 
rs35996865 18 18692344 T/G 0.7 ROCK1 upstream -2.33 0.46 3.17E-07 
rs1501127 4 16554662 T/C 0.81 LDB2 intron -2.38 0.52 5.14E-06 
rs1599951 3 28359788 A/G 0.87 CMC1 intron -2.5 0.62 5.48E-05 
rs55704326 3 28534629 A/T 0.86 ZCWPW2 intron -2.69 0.69 9.77E-05 
rs153452 5 150612619 A/G 0.89 GM2A intron -2.75 0.68 5.65E-05 
rs9544846 13 79121654 A/G 0.91 
RNF219-
AS1 
intron -2.83 0.7 5.67E-05 
rs10970978 9 32442256 A/G 0.88 ACO1 intron -2.93 0.67 1.02E-05 
rs17665445 3 29347554 A/G 0.88 RBMS3 intron -2.99 0.68 9.70E-06 
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SNP chr 
position 
(bp) 
alleles 
risk 
allele 
freq 
gene location beta SE p-value 
rs153458 5 150607972 C/A 0.89 CCDC69 upstream -3.01 0.7 1.59E-05 
rs73226977 3 139928004 G/T 0.91 CLSTN2 intron -3.04 0.75 5.09E-05 
rs113551213 12 12513870 G/A 0.92 LOH12CR1 intron -3.31 0.85 9.70E-05 
rs7856710 9 15521362 G/A 0.94 RN7SL98P downstream -3.57 0.89 6.19E-05 
rs62571027 9 15515899 G/A 0.94 PSIP1 upstream -3.59 0.89 5.70E-05 
rs116435336 2 238563732 C/T 0.95 LRRFIP1 intron -3.66 0.94 9.15E-05 
rs34077724 16 81739784 G/T 0.95 CMIP intron -3.87 0.96 5.81E-05 
rs74870432 11 84932409 T/C 0.98 DLG2 intron -5.36 1.31 4.14E-05 
rs182304522 11 85216321 G/A 0.98 
RNU6-
1292P 
upstream -5.39 1.29 3.14E-05 
rs17487808 4 166024258 A/G 0.98 TMEM192 intron -5.51 1.4 8.44E-05 
rs79910493 12 102843754 C/T 0.98 IGF1 intron -5.94 1.46 4.60E-05 
rs7933179 11 85419919 C/T 0.97 SYTL2 intron -5.94 1.29 4.05E-06 
rs76472108 1 241304791 G/C 0.98 RGS7 intron -6.07 1.54 7.71E-05 
rs148974495 7 1577796 G/A 0.98 TMEM184A downstream -6.32 1.58 6.06E-05 
rs183544012 3 53747902 C/T 0.98 CACNA1D intron -6.46 1.57 3.93E-05 
rs72766128 9 115417463 C/T 0.98 KIAA1958 intron -6.71 1.64 4.14E-05 
rs150455300 4 79007274 C/T 0.98 FRAS1 intron -7.47 1.92 9.69E-05 
rs76156580 8 4474130 C/A 0.99 CSMD1 intron -8.53 2.16 7.98E-05 
rs148372781 3 124555852 G/A 0.99 ITGB5 intron -8.64 2.2 8.50E-05 
 
LVMh
2.7
 association was evaluated using a linear regression analysis under an 
additive model, adjusted for ancestry PCs, sex, SBP, DBP, serum creatinine, 
uNa24h, sPRA, BMI, HR, and echocardiography operator. To retrieve information 
about SNPs and their genomic context (the nearest gene) we used the hg19 
assembly (National Center for Biotechnology Information 37). SNP indicates single 
nucleotide polymorphism; chr, chromosome; bp, base pair; and SE, standard error.  
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Table A3 The loci of SNPs with less clear or direct role in cardiac 
hypertrophy, found in our study and their functional role in experimental 
setting. 
Lead SNPs 
Locus 
gene 
Gene description 
(official gene name is reported in Italic) 
rs76472108 RGS7 
Regulator Of G-Protein Signaling 7. Member of G-
protein signaling regulator family that fine-tunes G 
protein-coupled receptor-induced signaling. Changes 
in the RGS protein expression and/or function in the 
heart often lead to pathophysiological changes and 
are associated with cardiac disease in animals and 
humans, including hypertrophy, fibrosis development, 
heart failure, and arrhythmias.
a
 
rs17068332 
rs76156580 
CSMD1 
CUB and Sushi multiple domains protein 1. 
Transmembrane protein belonging to the vacuolar-
protein-sorting-13 family. CSMD1 gene was 
associated with peripheral arterial disease and 
metabolic syndrome.
b,c
 Moreover CSMD1 gene was 
associated with increased risk of hypertension in two 
case-control studies in Korean cohorts
d
. 
rs6590636 CNTN5 
Contactin 5. Member of the immunoglobulin 
superfamily, which mediates cell surface interactions 
during nervous system development and has been 
associated with atrial fibrillation and heart failure.
e
  
rs13023211 FIGN 
Fidgetin. Member of a family of ATPases associated 
with diverse cellular activities. Variants at this locus 
have been associated with blood pressure regulation 
and with pulse pressure and mean arterial pressure.
f,g
 
rs9284436 HCN2 
Hyperpolarization Activated Cyclic Nucleotide-Gated 
Potassium Channel 2. Voltage-gated potassium 
channel that contributes to spontaneous rhythmic 
activity in both heart and brain. HCN2 and HCN4 are 
the predominant HCN transcripts in ventricular cells 
under basal conditions. Several studies showed an 
increase in the mRNA levels of these two genes 
following the induction of hypertrophy, but other 
studies are in contrast with these results.
h
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